Gilead deep­ens its stake in As­sem­bly Bio­sciences; NGM li­cens­es out MASH drug

Plus, news about Abili­ta Ther­a­peu­tics, Ori­on, No­var­tis, XGEN Ven­ture, Palleon, Hen­lius, TigaTx, HER­Vo­lu­tion Ther­a­peu­tics and Krys­tal Biotech:

Gilead now owns 30% of As­sem­bly Bio­sciences: The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER